Abstract
Evaluating [18F]Fluorodeoxyglucose (FDG) Uptake as a Prognostic Metric in Stage IV Lung Cancer Patients Being Treated with Pharmacological Ascorbate and Chemotherapy
International journal of radiation oncology, biology, physics, Vol.123(1 Supplement), pp.e225-e226
09/2025
DOI: 10.1016/j.ijrobp.2025.06.3788
Abstract
Purpose/Objective(s)
Tumor glucose metabolism is thought to be intimately connected to redox metabolism through processes such as the pentose phosphate pathway for the generation of reducing equivalents (e.g., NADPH). Therefore, the use of [18F]Fluorodeoxyglucose (FDG) uptake as a surrogate marker of glucose metabolic rates may provide useful information into the relative sensitivity of tumors to redox metabolic therapies that have shown promise to enhance radiation and chemotherapy response (e.g., pharmacological ascorbate). This study is a retrospective secondary review of a single institutional phase II study of stage IV lung cancer patients who received pharmacological ascorbate and carboplatin/paclitaxel. The goal was to determine the prognostic value of FDG PET imaging in predicting patient outcomes (progression-free survival and overall survival). It is hypothesized that that FDG uptake correlates with patient outcomes (progression-free survival and/or overall survival) in patients with stage IV non-small cell lung cancer treated with pharmacological ascorbate and carboplatin/paclitaxel.
Materials/Methods
Thirty-eight patients participated in a single arm institutional phase II clinical trial for the treatment of stage IV non-small cell lung cancer, where eligible participants received 75 g ascorbate intravenously twice per week for 12 weeks in combination with carboplatin (AUC 6) and paclitaxel (200 mg/m2) every three weeks for 4 cycles. SUV-max, SUV-mean, SUV-volume, and SUV-total lesion activity above 3.5 from FDG PET/CT images were correlated with progression free survival and overall survival. Inclusion criteria of 18 years or older and SUV above 3.5. Thirty-four were included in final analysis since 4 died ≤ 15 days of starting therapy. Statistical analysis was performed with the computer program GraphPad Prizm 10. Two-variable correlation was performed utilizing simple non-linear regression.
Results
Median follow up for 34 patients on treatment was 1-month for the first 6-months, then every 3 to 6 months after. Progression free survival had a median of 6.4 months and median overall survival was 2.1 years. Of note four patients are alive at an average of 7.5 years follow up. On evaluation of prognostic indices both FDG SUV-volume and FDG SUV-total lesion activity were negatively correlated with progression free survival (r = -0.35, p = 0.05, [95% CI, -0.63 to -0.0008] and r = -0.41, p = 0.04, [95% CI, -.70 to -.025], respectively). SUV-volume and SUV-total lesion activity did not show significant correlations with respect to overall survival (r = 0.15 p = 0.40, [95% CI, 0.11 to 0.68] and r = 0.19 p = 0.29, [95% CI, -0.48 to 0.18], respectively).
Conclusion
High FDG tumors appeared more resistant to therapy with ascorbate and progressed faster than tumors with lower FDG uptake. These data indicate that FDG uptake may serve as a novel, non-invasive approach to assess clinical response to treatment for patients receiving pharmacological ascorbate that warrant further investigation.
Details
- Title: Subtitle
- Evaluating [18F]Fluorodeoxyglucose (FDG) Uptake as a Prognostic Metric in Stage IV Lung Cancer Patients Being Treated with Pharmacological Ascorbate and Chemotherapy
- Creators
- A.R. Way - University of IowaM.O. Evbuomwan - University of IowaO.A. Alegi - University of IowaM. Roozeboom - University of IowaS. Rajan - University of IowaU.A. Uzomah - University of IowaM. Furqan - University of IowaB.G. Allen - University of IowaD. Spitz - University of IowaM.S. Petronek - University of IowaM. Graham - University of Iowa
- Resource Type
- Abstract
- Publication Details
- International journal of radiation oncology, biology, physics, Vol.123(1 Supplement), pp.e225-e226
- DOI
- 10.1016/j.ijrobp.2025.06.3788
- ISSN
- 0360-3016
- Language
- English
- Date published
- 09/2025
- Academic Unit
- Radiology; Hematology, Oncology, and Blood & Marrow Transplantation; Pathology; Iowa Neuroscience Institute; Radiation Oncology; Fraternal Order of Eagles Diabetes Research Center; Internal Medicine
- Record Identifier
- 9984969111002771
Metrics
1 Record Views